Public Company Healthcare

Ipsen

Paris, France

Ipsen is a global biopharmaceutical company focused on bringing transformative medicines to patients in three therapeutic areas: Oncology, Rare Disease and Neuroscience.

Focus Areas
Biopharmaceuticals, Oncology therapeutics, Rare disease therapeutics
Website
www.ipsen.com

Tracked deals

3

3 tracked deals across 2023-2026.

Recent pace

2

2 tracked deals announced in the last 12 months.

Deal mix

Buyout

3 buyout

Ipsen Acquisition Volume by Year

Last 2 years

Acquisition volume by year Annual acquisition counts for the last 2 years for Ipsen. 1 2023 ~3 est. 2 2026
Actual Full-year estimate

Supporting Data

Recent Transactions

  • Ipsen Completes Acquisition of Kartos Therapeutics
    August 21, 2026
    Buyer
    Ipsen
    Target
    Kartos Therapeutics
    Industry
    Pharmaceuticals
    Location
    France
    Type
    Buyout

    Ipsen completed its acquisition of Kartos Therapeutics, adding the late-stage oncology drug navtemadlin (an oral MDM2 inhibitor) to its pipeline. Navtemadlin is in Phase III development as an add-on to ruxolitinib for patients with myelofibrosis who have a suboptimal response to standard therapy.

  • Ipsen Acquires Kartos Therapeutics for Up to $1.75 Billion
    June 29, 2026
    Buyer
    Ipsen
    Target
    Kartos Therapeutics
    Industry
    Biotechnology
    Location
    France
    Type
    Buyout

    Ipsen entered into a definitive merger agreement to acquire clinical-stage biopharmaceutical company Kartos Therapeutics. The deal brings navtemadlin, an oral MDM2 inhibitor in Phase III for TP53 wild-type myelofibrosis, into Ipsen’s late-stage oncology pipeline, with $450 million paid upfront and up to $1.3 billion in regulatory and sales-related milestones.

  • Ipsen Acquires Albireo Pharma
    January 9, 2023
    Buyer
    Ipsen
    Target
    Albireo Pharma, Inc.
    Industry
    Biotechnology
    Location
    Massachusetts, United States
    Type
    Buyout

    Ipsen has agreed to acquire Albireo Pharma in a cash tender offer of $42.00 per share plus a contingent value right (CVR) tied to FDA approval in biliary atresia, in a transaction intended to expand Ipsen's Rare Disease portfolio. The acquisition brings Albireo's approved pediatric liver drug Bylvay (odevixibat) and a pipeline of bile-acid modulators into Ipsen's global R&D and commercial capabilities.

Related Acquisition Pages

Biotechnology Buyers & Acquisitions 2 tracked deals by Ipsen. Pharmaceuticals Buyers & Acquisitions 1 tracked deal by Ipsen. Acquisitions in Massachusetts 1 tracked deal by Ipsen.

Related articles

Selling a company? Get in front of buyers like Ipsen

Turn tracked acquisition activity into an outreach-ready buyer list.

Find buyers like these →